同时,inclisiran可以保存至预填充注射器,方便使用,其安全性也得到了证实。此外,inclisiran降脂效果强且作用持久。 来自梅奥诊所的Wright表示,降低LDL-C水平是延缓动脉粥样硬化性心血管疾病最有效的干预措施,我们迫切需要除目前临床上常用的降低LDL-C...
Aim: To analyze efficacy and safety of inclisiran (small interfering RNA targeting hepatic PCSK9 mRNA) across the strata of glycemic disorders. Methods: In this post hoc, pooled analysis of ORION-10 and ORION-11, 3174 patients (pts) with ASCVD/ASCVD risk equivalent (including diabetes ...
最后Watson总结道,Inclisiran是siRNA类中第一个降低胆固醇的药物,它开辟了一种全新的、令人兴奋的可能性,增加有效治疗方案的数量和种类,让我们的病人有更多的选择。 文献引用: 1. Wright RS. ORION-10: inclisiran for subjects with ASCVD and elevated low-density lipoprotein cholesterol. Presented at: AHA 20...
ORION-1二期剂量试验表明,inclisiran,一种靶向肝细胞PCSK9合成的小干扰RNA(siRNA),不频繁给药(每六个月一次)可安全降低50%的LDL-C。ORION-10是一项评估inclisran治疗ASCVD和LDL-C升高患者的疗效和安全性的3期试验。 Methods:ORION-10 is a Phase 3, placebo-controlled, double-blind, randomized study in 15...
Abstract 11033: Efficacy and Safety of Inclisiran by Baseline Glycemic Status: A Post Hoc Pooled Analysis of the ORION-10 and ORION-11 Phase III Randomized Controlled TrialsAtherosclerosisDiabetes (Type II)GlucoseCholesterol-lowering drugsIntroduction:\nDisorders of glucose metabolism increase in ...
(PCSK9) resulted in reduced low-density lipoprotein cholesterol (LDL-C) concentration and MACE incidence in pts with PVD.[3,4] Inclisiran is a small interfering RNA (siRNA) agent targeting PCSK9 messenger RNA that provided effective and sustained reduction in LDL-C concentration and was well ...
InclisiranLDL-CASCVDPolyvascular diseasePatients with polyvascular disease (PVD) are at very high cardiovascular risk and require intensive lipid-lowering therapy. This analysis describes the lipid-lowering efficacy and safety of inclisiran versus placebo in patients with and without PVD.#In this ...